PPARG and juvenile Huntington disease: VCE-003.2 showed neuroprotective effects in a murine model of Huntington’s disease that was prevented by co-administration of the PPARγ antagonist T0070907 and in a murine model of Parkinson’s disease [114,115,116,117].